ASCO 2015: Cancer research brings new and better therapies to patients

May 26, 2015 | by Nicole Levine

Anyone who tours City of Hope will almost certainly be taken by two key buildings: City of Hope Helford Clinical Research Hospital and the Arnold and Mabel Beckman Center for Cancer Immunotherapeutics & Tumor Immunology.

 

cancer research City of Hope scientists will share their cancer research breakthroughs at the ASCO 2015 annual meeting in Chicago.

 

The heart of the campus, in more ways than one, the two buildings are a stone's throw from each other. The hospital is dedicated to treating cancer patients who are currently fighting their disease, and the research institute to finding the treatments and cures these patients need – and efficiently bringing those innovations to the clinic.

That drive to help patients is what inspires so many City of Hope physicians and scientists to attend, and present research at, medical conferences. There, they can share their discoveries with their peers worldwide, as well as learn about new advances and developments in cancer research and care. One of the most notable of those conferences will take place this week in Chicago.

Thousands of researchers and physicians will convene in Chicago May 29 through June 2 for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, including a delegation from City of Hope who will share findings about a number of cancers and treatment approaches, including assessments of potential new therapies and comparisons of current therapies. 

The array of research from City of Hope is both far-ranging and impressive in its depth, said Steven T. Rosen, M.D., provost and chief scientific officer at City of Hope. "This illustrates the productivity of our faculty and their contribution to advancing cancer care," he said.

Some of these findings are already being shared with the public via the ASCO website:

  • Randomized phase II evaluation of tivantinib and tivantinib in combination with erlotinib in patients with papillary renal cell carcinoma. Read more.
  • A study examining a PARP inhibitor combined with carboplantin or as a single agent followed by post-progression therapy for patient with BRCA-associated metastatic breast cancer. Read more.
  • A phase II trial for patients with metastatic pancreatic cancer, examining a drug that targets KRAS mutations, which are present in 90 percent of pancreatic cancers. Read more.
  • A study evaluating a combination of drugs that is promising for patients with nonsmall cell lung cancer. Read more.
  • A less toxic means of providing radiation for multiple myeloma patients using an image-guided technology to provide total marrow irradiation. Read more.
  • Study on the effect of the "lipogenic phenotype" in sarcomas, and how this phenotype reprograms the cancer's epigenome to enhance malignant potential. Read more.
  • A phase I study of a drug combination for aggressive relapsed or refractory lymphoma. Read more.
  • A study to fine-tune chemotherapy doses to reduce the risk of breast cancer recurrence. Read more.
  • Comprehensive genomic profiling of kidney cancer patients can reveal rare subtypes of the disease and potentially allow for targeted treatments based on the tumor's genetics. Read more.
  • Assessment of a multigene testing panel to determine breast cancer risk. Read more.
  • A study of providing an intraperitoneal therapy for patients with advanced cancers in the body cavity. Read more.
  • A trial-in-progress indicates that patients with metastatic desmoplastic melanoma respond better to anti-PD1/PDL1 therapy than other melanoma patients. Read more.

**

 

Learn more about becoming a patient or getting a second opinion by visiting our website or by calling 800-826-HOPE (4673). You may also request a new patient appointment online. City of Hope staff will explain what's required for a consult at City of Hope and help you determine, before you come in, whether or not your insurance will pay for the appointment.

Back To Top

Search Blogs